Zydus' Keytruda biosimilar accepted for USFDA review

Zydus' Keytruda biosimilar accepted for USFDA review. Zydus Lifesciences announced that FYB206, its biosimilar to Keytruda®, has been accepted for review by the USFDA. This marks the first publicly announced Keytruda biosimilar to reach this stage. The move positions Zydus for potential market entry in the high-value oncology segment.

📊 STOCKS: $ZYDUSLIFE | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma